Envestnet Asset Management Inc. Buys 11,499 Shares of Grifols, S.A. $GRFS

Envestnet Asset Management Inc. boosted its position in shares of Grifols, S.A. (NASDAQ:GRFS) by 4.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 286,192 shares of the biotechnology company’s stock after acquiring an additional 11,499 shares during the period. Envestnet Asset Management Inc.’s holdings in Grifols were worth $2,587,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of GRFS. Advisors Preferred LLC purchased a new position in shares of Grifols during the 1st quarter valued at $368,000. Vident Advisory LLC raised its holdings in Grifols by 134.5% during the first quarter. Vident Advisory LLC now owns 69,564 shares of the biotechnology company’s stock valued at $495,000 after acquiring an additional 39,902 shares during the period. Groupe la Francaise bought a new position in shares of Grifols in the first quarter worth about $1,699,000. Cetera Investment Advisers boosted its stake in shares of Grifols by 16.1% in the first quarter. Cetera Investment Advisers now owns 35,254 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 4,900 shares during the period. Finally, Natixis Advisors LLC grew its position in shares of Grifols by 20.3% during the first quarter. Natixis Advisors LLC now owns 212,585 shares of the biotechnology company’s stock worth $1,511,000 after purchasing an additional 35,865 shares in the last quarter.

Analysts Set New Price Targets

A number of brokerages have issued reports on GRFS. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Grifols in a report on Wednesday, October 8th. Wall Street Zen raised shares of Grifols from a “buy” rating to a “strong-buy” rating in a report on Saturday. Zacks Research downgraded Grifols from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Grifols in a research note on Tuesday, August 5th. One investment analyst has rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $10.30.

Grifols Trading Up 0.1%

GRFS opened at $8.71 on Monday. Grifols, S.A. has a 12 month low of $6.19 and a 12 month high of $11.14. The company has a current ratio of 2.64, a quick ratio of 0.95 and a debt-to-equity ratio of 1.20. The stock has a 50-day moving average of $9.49 and a 200 day moving average of $9.30. The firm has a market cap of $5.99 billion, a P/E ratio of 45.84, a P/E/G ratio of 0.32 and a beta of 0.69.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.